XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of “Hold” from Analysts

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have been assigned an average recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $60.60.

A number of equities analysts have recently issued reports on XOMA shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. UBS Group set a $76.00 target price on shares of XOMA Royalty in a report on Tuesday, December 9th. Stifel Nicolaus set a $50.00 price target on XOMA Royalty in a research note on Friday, December 12th. Leerink Partners lowered their price target on XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Finally, Wall Street Zen lowered XOMA Royalty from a “buy” rating to a “hold” rating in a report on Saturday, November 15th.

XOMA Royalty Stock Performance

NASDAQ XOMA opened at $24.97 on Friday. The business’s 50-day moving average price is $27.88 and its 200 day moving average price is $31.18. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. The firm has a market cap of $309.13 million, a P/E ratio of 33.74 and a beta of 0.89. XOMA Royalty has a 52-week low of $18.35 and a 52-week high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.33). XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. The firm had revenue of $9.35 million during the quarter, compared to analyst estimates of $11.47 million. On average, equities research analysts expect that XOMA Royalty will post -1.41 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Owen Hughes acquired 100,000 shares of XOMA Royalty stock in a transaction dated Thursday, December 4th. The shares were acquired at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the completion of the transaction, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at $2,555,100. The trade was a 5,000.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 9.10% of the company’s stock.

Institutional Investors Weigh In On XOMA Royalty

Several hedge funds have recently made changes to their positions in the business. State of Alaska Department of Revenue purchased a new position in XOMA Royalty during the fourth quarter worth about $27,000. Russell Investments Group Ltd. increased its stake in shares of XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the period. JPMorgan Chase & Co. boosted its position in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 543 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in XOMA Royalty in the second quarter valued at approximately $116,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.